MET mutation as an independent biomarker for favorable outcomes in pan-cancer immunotherapy. (IMAGE)

Compuscript Ltd

MET mutation as an independent biomarker for favorable outcomes in pan-cancer immunotherapy.

Caption

(A) Kaplan–Meier survival analysis stratified by MET mutation status in 2539 cancer patients with 7 tumor types treated with ICIs in the discovery cohort. (B) The association between MET mutation and OS in 1610 patients with 10 tumor types in the validation cohort. (C–E) The comparison of OS (C), PFS (D), and ORR (E) between patients with MET mutation and patients with MET non-mutation in 4149 subjects with 12 tumors treated with ICIs. (F, G) Univariate (F) and multivariate (G) Cox analyses of the association between MET mutation and OS in 4149 patients with 12 tumors treated with ICIs. (H) The nomogram for predicting the 12- and 24-month survival. It can calculate overall survival from the date of immunotherapy start. To use, users should locate the “age” axis and draw a line up to the “point” axis to get a score associated with age and repeat for the other features to get their scores. Afterward, the users sum all scores, locate it on the “total point” axis, and draw a line to the “12-month survival” axis to get the 12-month OS probability. (I) Calibration plots for validation of the 12- and 24-month survival from the nomogram in the discovery cohort. The average predicted probability (X-axis) was plotted against the observed Kaplan-Meier estimate in the subgroup (Y-axis, 95% CIs of the estimates are presented as vertical lines). The continuous line is the reference line, indicating what an optimal nomogram would be. (J, K) Based on the optimal cutoff value (total points = 60) derived from the nomogram, a low score was associated with favorable OS in both the discovery cohort (J) and validation cohort (K). CI, confidence interval; CUP, cancer of unknown primary; CR, complete response; EC, esophagogastric cancer; HNC, head and neck carcinoma; HR, hazard ratio; ICI, immune checkpoint inhibitor; LC, lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PD, progressive disease; PR, partial response; SD, stable disease.

Credit

Genes & Diseases

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.

License

CC BY-NC-ND

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.